This clinical trial is focused on studying a type of cancer called Large B-Cell Lymphoma, which is a form of non-Hodgkin lymphoma affecting the B-cells in the immune system. The study aims to compare the effectiveness and safety of a new treatment combination. This combination includes the drugs Glofitamab and Polatuzumab Vedotin, along with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone. These medications are used to target and destroy cancer cells, and they work in different ways to help treat the lymphoma.
The purpose of the study is to evaluate how well the combination of Glofitamab with the other drugs works compared to the standard treatment, which includes Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone. Participants in the study will receive one of these treatment combinations. The study will monitor the participants over a period to see how the cancer responds to the treatment and to check for any side effects. The study will also look at how long participants live without the cancer getting worse, which is known as progression-free survival.
Participants will be closely monitored throughout the study, which will include regular check-ups and tests to assess their health and the effectiveness of the treatment. The study is designed to provide valuable information on whether the new combination of drugs can offer better outcomes for patients with Large B-Cell Lymphoma compared to the existing standard treatment. This research could potentially lead to improved treatment options for individuals diagnosed with this type of lymphoma.



Belgium
Denmark
France
Germany
Italy
Poland
Spain